Approved indications
Soliqua 100/33 is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are inadequately controlled on basal insulin (less than 60 units daily) or on lixisenatide.

Off-label uses
It is not generally used off-label because it is specifically formulated and studied for adults with type 2 diabetes already needing basal insulin or lixisenatide; it is not indicated for type 1 diabetes or for use in diabetic ketoacidosis or in children.

Efficacy expectations
Many patients see improvements in fasting and after-meal blood sugars within days to weeks, with A1C reductions typically greater than those achieved by simply increasing basal insulin alone. In studies, more patients reached A1C targets with Soliqua 100/33 compared with basal insulin alone, often with less weight gain and a similar or lower risk of hypoglycemia than higher doses of basal insulin. As with other glucose-lowering medicines, individual results vary and best effects are seen when combined with diet, physical activity, and regular dose adjustment based on blood sugar monitoring.

Typical dosing and how to use
Soliqua 100/33 is given as a once-daily subcutaneous injection in the abdomen, thigh, or upper arm within the hour before the first meal of the day, using the prefilled pen. The pen delivers doses from 15 to 60 units; the starting dose and titration schedule are individualized based on the current basal insulin dose or prior lixisenatide use, with a maximum of 60 units once daily.

Special dosing instructions
Do not use Soliqua 100/33 in combination with another GLP-1 receptor agonist, and do not inject into a vein or muscle. Rotate injection sites within the chosen area to reduce the risk of lipodystrophy or skin irritation. Dose adjustments may be needed with changes in diet, physical activity, weight, kidney or liver function, or when adding or stopping other diabetes medicines.

Missed dose and overdose
If a dose is missed, skip the missed dose and take the next dose at the usual time the following day; do not take two doses on the same day. In case of overdose or suspected overdose (for example, taking more than prescribed or taking an extra dose), monitor for signs of low blood sugar and seek emergency medical help or contact a poison control center immediately.

Common side effects
The most common side effects include nausea, vomiting, diarrhea, decreased appetite, indigestion, and injection-site reactions; these are usually mild to moderate and often lessen over time. Low blood sugar (hypoglycemia) can occur, especially when Soliqua 100/33 is used with other medicines that lower blood sugar such as sulfonylureas.

Serious or rare adverse effects
Serious reactions that need immediate medical attention include severe allergic reactions (rash, swelling of face or throat, trouble breathing), severe abdominal pain that may spread to the back (possible pancreatitis), signs of severe hypoglycemia (confusion, seizures, loss of consciousness), and symptoms of kidney problems (reduced urination, swelling in legs or feet). Gallbladder problems and worsening of existing kidney disease have been reported with GLP-1 receptor agonists such as lixisenatide.

Warnings and precautions
Soliqua 100/33 is not for people with type 1 diabetes or for treating diabetic ketoacidosis. It should be used cautiously in patients with a history of pancreatitis, severe gastrointestinal disease (such as gastroparesis), or significant kidney impairment, and dose adjustments or closer monitoring may be needed. It is not recommended in pregnancy or breastfeeding unless the potential benefit clearly outweighs potential risks, and it has not been established as safe and effective in pediatric patients. Alcohol may increase the risk of hypoglycemia and should be used with care.

Safety compared to similar drugs and reporting
Its safety profile is generally similar to that of other long-acting insulins combined with GLP-1 receptor agonists, with gastrointestinal side effects more common from the GLP-1 component and hypoglycemia risk related mainly to total insulin exposure. Patients and caregivers can report side effects to the FDA MedWatch program or to the manufacturer and should check official prescribing information or FDA safety communications for updates on warnings or new adverse-event information.

Drug and other interactions
Medicines that lower blood sugar, such as sulfonylureas or insulin secretagogues, can increase the risk of hypoglycemia when used with Soliqua 100/33 and may require dose reductions. Certain drugs, including corticosteroids, some diuretics, and sympathomimetics, may raise blood sugar and reduce the effect of Soliqua 100/33. Because lixisenatide slows stomach emptying, it can affect how quickly other oral medicines are absorbed; drugs that need fast absorption or have a narrow therapeutic window may need special timing or monitoring. Alcohol can increase the risk of both low and high blood sugar and should be used cautiously.

Precautions and conditions needing caution
Use with caution in patients with a history of pancreatitis, severe gastrointestinal disease (including gastroparesis), or moderate to severe kidney impairment. It should not be used in type 1 diabetes or for diabetic ketoacidosis. Dose or regimen adjustments and close monitoring may be needed when starting or stopping other diabetes medications or drugs that affect blood sugar.

Monitoring needs
Regular blood glucose monitoring and periodic A1C testing are important to guide dose adjustments and assess long-term control. Kidney function should be assessed at baseline and monitored periodically, especially in patients with preexisting kidney disease or at risk of dehydration from gastrointestinal side effects. Healthcare professionals may also monitor weight, injection sites, and symptoms suggestive of pancreatitis or gallbladder disease.

Q: How often do I take Soliqua 100/33 and when should I inject it?
A: Soliqua 100/33 is injected once daily under the skin within 1 hour before your first meal of the day, at about the same time each day.

Q: Can Soliqua 100/33 be used as my first insulin or first diabetes medicine?
A: No, Soliqua 100/33 is intended for adults with type 2 diabetes who are already using basal insulin or lixisenatide and still need better control; it is not recommended as initial therapy for diabetes.

Q: What should I do if I feel nauseated after starting Soliqua 100/33?
A: Mild nausea is common when starting or increasing the dose and often improves over time; eating smaller meals, avoiding very fatty foods, and talking with your healthcare provider about the pace of dose increases can help.

Q: Can I use Soliqua 100/33 with other GLP-1 medicines?
A: No, you should not use Soliqua 100/33 together with another GLP-1 receptor agonist, because this can increase side effects without proven additional benefit.

Q: How soon will my blood sugar and A1C improve with Soliqua 100/33?
A: Blood sugar levels may improve within days to weeks after starting and adjusting your dose, while A1C typically reflects changes over about 3 months, depending on your overall diabetes plan and adherence.

Storage before first use
Keep Soliqua 100/33 pens in the refrigerator (36°F to 46°F / 2°C to 8°C), protected from light, and do not freeze; throw away any pen that has been frozen.

Storage in use
After first use, keep the pen at room temperature (below 77°F / 25°C), away from heat and direct sunlight, and discard 28 days after first use even if some medicine remains.

Handling and disposal
Do not use the pen if the solution looks cloudy, colored, or contains particles, or if the pen is damaged. Use a new needle for each injection and throw used needles and pens away in a puncture‑resistant sharps container according to local regulations; do not throw loose needles into household trash or recycling.